Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 1, Issue 3

September 16 2024

In this Issue

REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
RESEARCH LETTERS

REVIEW ARTICLE

Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice

Natalia Timofeeva,Nitin Jain,Varsha Gandhi

View Articletitled, Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice

CLINICAL TRIALS AND OBSERVATIONS

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Clinical Trials & Observations

Jad Othman,Ho Pui Jeff Lam,Sarah Leong,Faisal Basheer,Islam Abdallah,Kathryn Fleming,Priyanka Mehta,Heba Yassin,John Laurie,Michael Austin,Paolo Gallipoli,Tom Taylor,Mike Dennis,Johnathon Elliot,Georgina Clarke,Raymond Dang,Jennifer Vidler,Pramila Krishnamurthy,Anne-Louise Latif,Pallavi Kalkur,Maryam Shahidianakbar,Victoria Campbell,Deepak Mannari,Emily Sutherland,Thishakya Wickramaratne,Angela Collins,Rui Zhao,Herng Mak,Edward Belsham,Shabnam Banerjee,Jamila Bashir,Srinivas Pillai,Richard Whitmill,Sofia Galli,Mariam Amer,Vidhya Murthy,Duncan Murray,Farooq Wandroo,Francesca Hogan,Francesca Crolla,Nicole Fowler,Anjum Khan,Jenny O’Nions,Richard Dillon

View Articletitled, Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS

Supplemental data

Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial
Clinical Trials & Observations

Ulrich Dührsen,Andreas Bockisch,Bernd Hertenstein,Imke E. Karsten,Frank Kroschinsky,Michael Heuser,Andreas Hochhaus,Heinz-Gert Höffkes,Dirk Behringer,Gabriele Prange-Krex,Mareike Tometten,Martin Grieshammer,Götz U. Grigoleit,Oliver Schmalz,Karin Jordan,Helga Bernhard,Tobias Gaska,Aristoteles Giagounidis,Roland Schroers,Uwe M. Martens,Gerhard Held,Wolfram Klapper,Karl-Heinz Jöckel,Michael Nonnemacher,Andreas Hüttmann,on behalf of the PETAL Trial Investigators

View Articletitled, Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial

Supplemental data

LYMPHOID NEOPLASIA

Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma

Christopher S. Strouse,Vanessa E. Siebert,Bradley T. Loeffler,Bradley D. McDowell,Brian J. Smith,Brian K. Link

View Articletitled, Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma

Supplemental data

Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system

Jun Y. Jiang,Chijioke Nze,Danielle Guffey,Rockbum Kim,Abiodun O. Oluyomi,Omar Rosales,Raka Bandyo,Courtney N. Miller-Chism,Mark M. Udden,Martha P. Mims,Hilary Ma,Gustavo A. Rivero,Akiva Diamond,Purnima S. Teegavarapu,Ang Li,Christopher R. Flowers

View Articletitled, Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system

Supplemental data

Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation

Nilanjan Ghosh,Ruibin Wang,Zaina P. Qureshi,Zhijie Ding,Marie-Hélène Lafeuille,Bruno Emond,Bronwyn Moore,Jinghua He,Alex Bokun,Heena Mavani,Kerry A. Rogers

View Articletitled, Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation

Supplemental data

Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

Priya Choudhry,Corynn Kasap,Bonell Patiño-Escobar,Olivia Gugliemini,Huimin Geng,Vishesh Sarin,Amrik Kang,Audrey Kishishita,Sham Rampersaud,Letitia Sarah,Yu-Hsiu T. Lin,Neha Paranjape,Poornima Ramkumar,Jonathan C. Patton,Makeba Marcoulis,Donghui Wang,Paul Phojanakong,Veronica Steri,Byron Hann,Benjamin G. Barwick,Martin Kampmann,Arun P. Wiita

View Articletitled, Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

Supplemental data

Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study

Koji Nagafuji,Toshihiro Miyamoto,Tetsuya Eto,Tomohiko Kamimura,Koji Kato,Yasuhiko Miyazaki,Atsushi Wake,Kentaro Kohno,Ken Takase,Yutaka Imamura,Naoyuki Uchida,Kazuki Tanimoto,Noriaki Kawano,Toshiro Kurokawa,Yukio Kondo,Yoshikiyo Ito,Tomoaki Fujisaki,Junichi Tsukada,Koji Yonemoto,Toshinori Hori,Koichi Akashi

View Articletitled, Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study

Supplemental data

MYELOID NEOPLASIA

Instructive interaction between myelodysplastic hematopoiesis and the bone marrow microenvironment at the single-cell level

Johann-Christoph Jann,Nanni Schmitt,Alexander Streuer,Qingyu Xu,Vladimir Riabov,Eva Altrock,Nadine Weimer,Verena Nowak,Julia Obländer,Iris Palme,Melda Göl,Marie Demmerle,Felicitas Rapp,Fabian Siegel,Laurenz Steiner,Mahmoud Ghazal,Angelika Duda,Verena Haselmann,Ali Darwich,Ahmed Jawhar,Mohamad Jawhar,Georgia Metzgeroth,Wolf-Karsten Hofmann,Daniel Nowak

View Articletitled, Instructive interaction between myelodysplastic hematopoiesis and the bone marrow microenvironment at the single-cell level

Supplemental data

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
Clinical Trials & Observations

Paul G. Kemps,F. J. Sherida H. Woei-A-Jin,Patrick Schöffski,Thomas Tousseyn,Isabelle Vanden Bempt,Friederike A. G. Meyer-Wentrup,Natasja Dors,Natasha K. A. van Eijkelenburg,Marijn A. Scheijde-Vermeulen,Ingrid M. Jazet,Maarten Limper,Margot Jak,Robert M. Verdijk,Marjolein L. Donker,Nick A. de Jonge,Carel J. M. van Noesel,Konnie M. Hebeda,Suzanne van Dorp,Sanne H. Tonino,Jan A. M. van Laar,Cor van den Bos,Astrid G. S. van Halteren,on behalf of the HOVON Histiocytic and Lymphocytic Diseases Working Group

View Articletitled, Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium

Supplemental data

RESEARCH LETTERS

An EMT-like signature as a potential driver of myeloid sarcoma

Kristin E. Zorn,Juliana Alvarez-Argote,Alison E. Meyer,Ashley Cunningham,Maria Hintzke,Emily Giever,Cary Stelloh,Ehab Atallah,George S. Vassiliou,Sridhar Rao

View Articletitled, An EMT-like signature as a potential driver of myeloid sarcoma

Supplemental data

Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study

Amy E. DeZern,Johannes B. Goll,Travis L. Jensen,Sridhar Nonavinkere Srivatsan,Nancy K. Gillis,Gregory A. Abel,Eric Padron,H. Joachim Deeg,Tareq Al Baghdadi,Jane Jijun Liu,Rami S. Komrokji,Steven D. Gore,Wael Saber,Rafael Bejar,Matthew J. Walter,R. Coleman Lindsley,Seth Sherman,Nancy DiFronzo,Mikkael A. Sekeres

View Articletitled, Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study

Supplemental data

Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia

Catia Simoes,Carmen Gonzalez,François Vergez,Audrey Sarry,Sarah Bertoli,Beñat Ariceta,David Martínez-Cuadrón,Juan-Miguel Bergua,Susana Vives,Lorenzo Algarra,Mar Tormo,Pilar Martinez,Josefina Serrano,Pilar Herrera,Fernando Ramos,Olga Salamero,Esperanza Lavilla,Cristina Gil,Jose-Luis Lopez-Lorenzo,Maria-Belen Vidriales,Carmen Chillon,Jorge Labrador,Jose-Francisco Falantes,María-José Sayas,Rosa Ayala,Joaquin Martinez-Lopez,Sara Villar,Maria-Jose Calasanz,Felipe Prosper,Jesús F. San-Miguel,Miguel Á. Sanz,Christian Récher,Bruno Paiva,Pau Montesinos,on behalf of the PETHEMA Cooperative Study Group

View Articletitled, Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia

Supplemental data

Effect of clofarabine and fludarabine exposure on outcome after pediatric allogeneic hematopoietic cell transplantation

Linde Dekker,Coco C. H. de Koning,A. Laura Nijstad,Kim C. M. van der Elst,Rick Admiraal,A. Birgitta Versluijs,Jaap Jan Boelens,Alwin D. R. Huitema,Caroline A. Lindemans,Stefan Nierkens

View Articletitled, Effect of clofarabine and fludarabine exposure on outcome after pediatric allogeneic hematopoietic cell transplantation

Supplemental data

T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions

Emma Kroeze,Michelle M. Kleisman,Rico Hagelaar,Reno S. Bladergroen,Lennart A. Kester,Marijn A. Scheijde-Vermeulen,Freerk van Dijk,Jules P. P. Meijerink,Roland P. Kuiper,Jan L. C. Loeffen

View Articletitled, T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions

Supplemental data

Cover Image

Cover Image

Single-cell uniform manifold approximation and projection analysis of primary bone marrow stroma and hematopoietic cells from patients with myelodysplastic neoplasms. See the article by Jann et al.

All Issues

Advertisement intended for health care professionals

Table of Contents

REVIEW ARTICLE

Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice

CLINICAL TRIALS AND OBSERVATIONS

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Clinical Trials & Observations

Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial
Clinical Trials & Observations

LYMPHOID NEOPLASIA

Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma

Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system

Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation

Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study

MYELOID NEOPLASIA

Instructive interaction between myelodysplastic hematopoiesis and the bone marrow microenvironment at the single-cell level

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
Clinical Trials & Observations

RESEARCH LETTERS

An EMT-like signature as a potential driver of myeloid sarcoma

Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study

Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia

Effect of clofarabine and fludarabine exposure on outcome after pediatric allogeneic hematopoietic cell transplantation

T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

REVIEW ARTICLE

CLINICAL TRIALS AND OBSERVATIONS

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS Clinical Trials & Observations

Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial Clinical Trials & Observations

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium Clinical Trials & Observations

RESEARCH LETTERS

Cover Image

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Clinical Trials & Observations

Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial
Clinical Trials & Observations

Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
Clinical Trials & Observations